Newsletter | May 11, 2021

05.11.21 -- Lung Cancer Treatment By Inhaled Formulations

 
Spray-Dry Manufacturing Formulations For Local Lung Cancer Treatment
 

Lung cancer accounts for 23% of all cancer-related deaths in American adults. Though a number of monoclonal antibody (mAb) treatments utilizing parenteral delivery have been commercialized, local delivery has to date been impossible. Recent advances in spray-drying technology show promising results, and potentially facilitate more effective mAbs through direct delivery to the lung.

Lung Cancer Treatment By Inhaled Formulations
 

Dry powder inhaled formulations have the potential to allow local treatment of lung cancer with decreased chemotherapeutic-related side effects. Explore the formulation and manufacturing of a topotecan inhaled dry powder and its use in decreasing tumor size in an animal model.

Spray-Dried Powders Enable Local Delivery For Lung Cancer
 

Spray-drying is a leading technology for particle engineering. It is particularly advantageous for manufacturing particles in the inhalable range of 1-5 microns. Learn more about spray drying through two case studies of inhaled dry powders.

A Q&A: Manufacturing Dry Powder Inhaled Formulations By Spray Drying
 

Understanding the spray-drying process and its challenges is critical to using this enabling technology for lung cancer indications. Dr. Kimberly Shepard, Ph.D., associate principal engineer in R&D, answers attendee questions from a recent webinar about the use of spray drying for today’s late-stage lung cancer treatments.